Xenetic Biosciences (XBIO) News Today $4.33 +0.13 (+3.19%) As of 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Xenetic Biosciences IncAugust 27, 2024 | money.usnews.com3XB0.SG,0P0001N0OC,0 (3XB0.SG)July 24, 2024 | finance.yahoo.comXenetic Biosciences Inc (XBIO)April 10, 2024 | investing.comXenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 24, 2024 | finance.yahoo.comXenetic Dips on Full-Year ResultsMarch 22, 2024 | baystreet.caXenetic Biosciences reports FY resultsMarch 22, 2024 | msn.comXenetic to advance DNase programme with UVA partnershipJanuary 18, 2024 | msn.comXenetic Biosciences Inc XBIOJanuary 4, 2024 | morningstar.comXenetic Biosciences Stock (NASDAQ:XBIO), Guidance and ForecastDecember 11, 2023 | benzinga.comMost Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO CompensationNovember 30, 2023 | finance.yahoo.comXenetic Biosciences: Q3 Earnings InsightsNovember 10, 2023 | benzinga.comMediciNova: Q3 Earnings SnapshotNovember 10, 2023 | washingtonpost.comXenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceOctober 11, 2023 | finance.yahoo.comXenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?July 13, 2023 | msn.comTrading was temporarily halted for "XBIO" at 12:07 PM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "XBIO" at 12:07 PM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "XBIO" at 12:07 PM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "XBIO" at 10:05 AM with a stated reason of "LULD pause."May 15, 2023 | marketbeat.comTrading was temporarily halted for "XBIO" at 10:05 AM with a stated reason of "LULD pause."May 15, 2023 | marketbeat.comTrading was temporarily halted for "XBIO" at 09:05 AM with a stated reason of "LULD pause."May 15, 2023 | marketbeat.comTrading was temporarily halted for "XBIO" at 09:05 AM with a stated reason of "LULD pause."May 15, 2023 | marketbeat.comXenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business UpdateMay 11, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison | MorningstarMay 5, 2023 | morningstar.comXenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and DevelopmentMay 4, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. CullisonMay 3, 2023 | finance.yahoo.comHC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy RecommendationApril 12, 2023 | msn.comAnalysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO)April 12, 2023 | markets.businessinsider.comXenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase PlatformApril 11, 2023 | finance.yahoo.comJTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesMarch 16, 2023 | finanznachrichten.deJTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesMarch 16, 2023 | finance.yahoo.comXBIO Xenetic Biosciences, Inc.February 23, 2023 | seekingalpha.comXBIO.PH - | Stock Price & Latest News | ReutersFebruary 21, 2023 | reuters.comXenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with ChemotherapyJanuary 17, 2023 | finance.yahoo.comWhy We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At AllDecember 15, 2022 | finance.yahoo.comThis Is Why Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Looks AppropriateDecember 1, 2022 | finance.yahoo.comXenetic Biosciences Third Quarter 2022 Earnings: Beats ExpectationsNovember 12, 2022 | finance.yahoo.comXenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 7, 2022 | finance.yahoo.comXenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business UpdateAugust 12, 2022 | finance.yahoo.comXenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology EventJune 2, 2022 | finance.yahoo.comXenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment ConferenceMay 18, 2022 | finance.yahoo.comXenetic Biosciences reports Q1 resultsMay 12, 2022 | seekingalpha.comXenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 12, 2022 | finance.yahoo.comHC Wainwright & Co. Maintains Buy on Xenetic Biosciences, Lowers Price Target to $4May 2, 2022 | benzinga.comXenetic Biosciences expands pipeline with DNase based oncology platform from CLS TherapeuticsMay 2, 2022 | proactiveinvestors.comXenetic stock rises 10% on license deal for CLS Therapeutics' cancer drugs platformApril 27, 2022 | seekingalpha.comXenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic ModalitiesApril 27, 2022 | finance.yahoo.comXenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update | MorningstarMarch 24, 2022 | morningstar.comXenetic Biosciences GAAP EPS of -$0.55, revenue of $1.16MMarch 23, 2022 | seekingalpha.comXenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business UpdateMarch 23, 2022 | finance.yahoo.com'We are expanding the potential of CAR T cell therapy through the development of our XCART technology platform...' -Tweet From Xenetic BiosciencesDecember 11, 2021 | benzinga.com Get Xenetic Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIO Media Mentions By Week XBIO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. XBIO News Sentiment▼0.440.74▲Average Medical News Sentiment XBIO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. XBIO Articles This Week▼20▲XBIO Articles Average Week Get Xenetic Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for XBIO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CARA News Today EQ News Today ENLV News Today LVTX News Today LPCN News Today SLGL News Today LGVN News Today NXTC News Today FBRX News Today LSTA News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:XBIO) was last updated on 1/30/2025 by MarketBeat.com Staff From Our PartnersI was wrong. Dead wrong. I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s New AI Move Could Trigger Massive Melt UPIn his first week in office, President Trump already revoked President Biden's disastrous AI executive order.....InvestorPlace | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenetic Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
